Ethics, policy, and rare genetic disorders: the case of Gaucher disease in Israel
- PMID: 12400900
- DOI: 10.1023/a:1020324332620
Ethics, policy, and rare genetic disorders: the case of Gaucher disease in Israel
Abstract
Gaucher disease is a rare, chronic, ethnic-specific genetic disorder affecting Jews of Eastern European descent. It is extremely expensive to treat and presents difficult dilemmas for officials and patients in Israel where many patients live. First, high-cost, high-benefit, but low volume treatment for Gaucher creates severe allocation dilemmas for policy makers. Allocation policies driven by cost effectiveness, age, opportunity or need make it difficult to justify funding. Process oriented decision making based on terms of fair cooperation or decisions invoking the "rule of rescue" risk discriminating against minorities who may already suffer from inequitable distribution of heath care resources. Apart from cost, Gaucher disease prompts questions about abortion. Unlike severe genetic disorders, Gaucher offers no grounds for abortion and, in many ways, is analogous to gender based abortions that are prohibited regardless of fetal age. Finally, Gaucher raises concerns about the disclosure of genetic information. These affect potential carriers asked to participate in population studies and carriers and patients who must consider disclosure to others. These concerns weigh the right to privacy against communal interests and bilateral commitments.
Similar articles
-
Prenatal panel screening considerations for non-neuronopathic Gaucher disease in the Ashkenazi-Jewish population.Isr Med Assoc J. 2006 May;8(5):347-50. Isr Med Assoc J. 2006. PMID: 16805236 Review.
-
Ethical aspects of genetic screening in Israel.Sci Context. 1998 Autumn-Winter;11(3-4):419-29. doi: 10.1017/s0269889700003112. Sci Context. 1998. PMID: 15168671
-
Look before you leap. Carrier screening for type 1 Gaucher disease: difficult questions.Eur J Hum Genet. 2008 Feb;16(2):139-40. doi: 10.1038/sj.ejhg.5201960. Epub 2007 Nov 28. Eur J Hum Genet. 2008. PMID: 18043719 No abstract available.
-
Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.JAMA. 2007 Sep 19;298(11):1281-90. doi: 10.1001/jama.298.11.1281. JAMA. 2007. PMID: 17878420
-
Public healthcare resource allocation and the Rule of Rescue.J Med Ethics. 2008 Jul;34(7):540-4. doi: 10.1136/jme.2007.021790. J Med Ethics. 2008. PMID: 18591290 Review.
Cited by
-
A systematic review of moral reasons on orphan drug reimbursement.Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y. Orphanet J Rare Dis. 2021. PMID: 34193232 Free PMC article.
-
Genetic Testing for Rare Diseases: A Systematic Review of Ethical Aspects.Front Genet. 2022 Jan 26;12:701988. doi: 10.3389/fgene.2021.701988. eCollection 2021. Front Genet. 2022. PMID: 35154238 Free PMC article. Review.
-
Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease.Pharmacoeconomics. 2007;25(3):201-8. doi: 10.2165/00019053-200725030-00003. Pharmacoeconomics. 2007. PMID: 17335306
-
The ethical framework for performing research with rare inherited neurometabolic disease patients.Eur J Pediatr. 2017 Mar;176(3):395-405. doi: 10.1007/s00431-017-2852-9. Epub 2017 Jan 16. Eur J Pediatr. 2017. PMID: 28093642 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical